Our research examines how human skin ages, inflames, breaks down, and repairs itself — and the biological mechanisms that shape each process. We are currently focused on major areas of skin health where better human-relevant models can deepen biological understanding and improve how skin responses are studied across donors and over time.
The skin’s outermost layer retains moisture, blocks irritants, and helps mediate the body’s relationship with the outside world. When this barrier breaks down, consequences can range from chronic dryness to eczema, infection, and sensitive skin. Meaningful barrier repair depends on more than surface hydration; it involves lipid organization, tissue integrity, and coordinated repair over time.
Skin aging is a multifaceted process shaped by senescent-cell accumulation, chronic low-grade inflammation, impaired repair, oxidative and environmental stress, and progressive degradation of collagen and elastin. These processes interact over time, reducing tissue resilience and allowing damage to accumulate as repair capacity declines.
Chronic inflammatory skin conditions are driven by sustained immune signaling, barrier dysfunction, epidermal stress, and tissue remodeling. In conditions such as psoriasis, these responses persist over time and involve coordinated changes across cytokine pathways, immune-cell activity, keratinocyte activation, and repair programs. Understanding this biology is essential for evaluating anti-inflammatory and immunomodulatory interventions.
Dyspigmentation and uneven skin tone affect many skin types. While core pigmentation biology is conserved, melanin regulation, inflammation-associated pigmentation, and treatment responses can vary across Fitzpatrick skin types and donor backgrounds.
Wound healing coordinates inflammation, cell migration, re-epithelialization, new tissue formation, and matrix remodeling over days to weeks. When this process is delayed or dysregulated, tissue damage can persist and progress toward chronic, non-healing wounds.
Cutaneous toxicity and adverse skin reactions can be common and clinically important across therapeutic and biologic interventions, from targeted therapies to vaccines and antibody-drug conjugates. These responses can involve tissue injury, inflammatory or immune-mediated signaling, target-associated effects, and patient-specific susceptibility.
September 29, 2026
Peer-reviewed proof of Yuna, our ex vivo platform that keeps full-thickness human skin alive, intact, and immune-active for 4+ weeks.
May 19, 2026
A next generation Human Skin platform for bioactive discovery
May 5, 2026
Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention. DOI 10.64898/2026.04.30.721933
March 25, 2026
An immunocompetent ex vivo human skin platform with extended viability for evaluating antibody-drug conjugate-induced skin toxicity. Abstract 5194, Poster K758.
March 15, 2026
A clinically relevant ex vivo human skin model for long-term assessment of inflammation and therapeutic interventions
February 23, 2026
Exploring an Advanced Human Skin Research Platform: Enabling Long-term & Immune-Competent Evaluation of ADC-Induced Cutaneous Toxicity
May 8, 2025
Advanced human skin platform for accelerated bioactive discovery
October 14, 2024
Outer Bio was named a top 10 finalist for the Applied Research Award at the International Federation of Societies of Cosmetic Chemists (IFSCC) 2024 Iguazu falls congress.
We're open to scientific collaborations. If you’re working on problems where human-relevant skin biology matters, reach out.
